AcrySof IQ Vivity and Clareon Vivity EDOF IOLs Reach 1 Million Implants Milestone
Alcon announced that the AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) IOLs have surpassed more than 1 million implants worldwide. Vivity is the most implanted EDOF IOL globally, according to Alcon.[1]
“We are proud to celebrate the one million Vivity eyes empowering cataract patients to see the world with high quality vision from distance to functional near—day and night,” Sean Clark, President, Global Surgical Franchise at Alcon, said in a company news release. “This milestone embodies our commitment to addressing the diverse vision needs of today's patients, who desire less dependence on glasses post-surgery and low visual disturbances, with a game-changing presbyopia-correcting intraocular lens (PCIOL) option that expands the patient candidacy pool.”
Vivity uses Alcon’s patented non-diffractive Wavefront-Shaping X-WAVE technology, an optical principle that simultaneously stretches and shifts light without splitting it, designed to balance quality of vision and maximizing range of vision.[2,3] The optic is designed to deliver excellent distance and intermediate vision, as well as functional near vision.[2] The mechanism of action is not refractive, does not introduce spherical aberrations, and has ultimately expanded PCIOL access to even more patients, according to Alcon. Vivity is designed to simplify presbyopia correction, prioritizing patient satisfaction while minimizing surgeon and clinic chair time.
Vivity is available in more than 80 countries, including Australia, Brazil, Canada, China, France, Germany, Japan, India, Italy, Russia, South Korea, Spain, U.K. and U.S.
References
- Market Scope - 2023 Premium Cataract Surgery Market Report; 2023 IOL Market Report.
- Alcon Data on File; U.S. Pat. Nos. RE45,969, 9,968,440, 11,083,566.
- AcrySof® IQ Vivity® or Clareon® Vivity® IOL Directions for Use.
- Reus NJ, Kooijman M, Perez-Vives C. Overall Visual Outcomes from a Real-world Study of Presbyopia-correcting IOLs in a Large Population. Presented at the European Society of Cataract and Refractive Surgery (ESCRS) Annual Meeting; 8-12 Sept. 2023; Vienna, Austria.
- Alcon Data on File, 2024. REF-22137.
- Alcon IOL Global Sales; Jan. 2021-Nov. 2022.
*Based on independent market audit - Market Scope - 2023 Premium Cataract Surgery Market Report.
+The Vivity® Registry Study was a multicentre, ambispective, non-comparative, open-label, non-interventional registry study conducted across 41 sites from eight (8) countries: Australia, Belgium, Germany, New Zealand, the Netherlands, Portugal, Spain and the United Kingdom.
∞Subject satisfaction was evaluated with the Catquest 9SF Questionnaire. Statistic refers to ‘very’ or ‘fairly’ satisfied.
†Visual disturbances were evaluated by asking open, non-prompted questions about visual experience.